Figures & data
Figure 1. Survival of patients enrolled in RTOG 9704 stratified by dCK expression level. Disease-free and overall survival for all evaluable patients (A and B), patients on the gemcitabine arm (C and D) and patients on the 5-FU arm (E and F).
Table 1. Hazard ratios for OS and DFS based upon dCK expression (high vs. low [reference level]) patients treated with gemcitabine or 5-FU
Figure 2. Inhibition of dCK in pancreatic cancer cells impairs 5-FU efficacy. MiaPaCa2 cells. (A) RT-qPCR validation of dCK silencing using siRNA oligos. (B) Improved cell survival after 5-FU treatment in cells with decreased dCK expression.
Table 2. Association between dCK status and HuR levels
Figure 3. Gemcitabine prior to radiation (XRT) is more efficacious than gemcitabine (GEM) alone or XRT prior to GEM due to differential modulation of HuR and dCK proteins. (A) Anchorage-independent colony formation assays were performed for quantification of colonies formation in MiaPaCa2 cells treated with gemcitabine (1 uM) alone or with gemcitabine preceded or followed by radiation (2 Gy). (B) PicoGreen cell survival assay on cells treated with radiation or with gemcitabine preceded or followed by radiation. (C) PicoGreen cell survival assay after HuR silencing with siRNA oligos. (D) RT-qPCR validation of HuR siRNA treatment in MiaPaCa2 cells. (E) Western blot for dCK, HuR, and α-tubulin (loading control) on lysates obtained from cells treated with gemcitabine alone, radiation alone, gemcitabine prior to radiation and radiation prior to gemcitabine.
